Capital Fund Management S.A. Fate Therapeutics Inc Transaction History

Capital Fund Management S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $1.11 Million - $1.53 Million	232,494 Added 324.66%	304,105 $1.45 Million
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $160,844 - $421,837	-37,935 Reduced 34.63%	71,611 $408,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $1.08 Million - $2.61 Million	109,546 New	109,546 $1.11 Million
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $917,092 - $2.43 Million	-24,077 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $120,636 - $160,663	3,967 Added 19.73%	24,077 $962,000
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $406,423 - $708,475	20,110 New	20,110 $689,000
Q1 2020 May 13, 2020	SELL	$17.28 - $31.88 $345,617 - $637,631	-20,001 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$13.39 - $20.73 $267,813 - $414,620	20,001 New	20,001 $391,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.